Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPensionProperty, Plant & Equipment (Net)Retained EarningsShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abivax (ABVX) Total Liabilities (2021 - 2025)

Historic Total Liabilities for Abivax (ABVX) over the last 5 years, with Q3 2025 value amounting to $164.6 million.

  • Abivax's Total Liabilities changed N/A to $164.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $164.6 million, marking a year-over-year change of. This contributed to the annual value of $168.7 million for FY2024, which is 2546.75% up from last year.
  • Per Abivax's latest filing, its Total Liabilities stood at $164.6 million for Q3 2025.
  • Abivax's Total Liabilities' 5-year high stood at $190.1 million during Q2 2025, with a 5-year trough of $66.6 million in Q4 2022.
  • Moreover, its 5-year median value for Total Liabilities was $166.6 million (2024), whereas its average is $146.0 million.
  • As far as peak fluctuations go, Abivax's Total Liabilities plummeted by 2736.4% in 2022, and later surged by 10077.42% in 2023.
  • Over the past 5 years, Abivax's Total Liabilities (Quarter) stood at $91.7 million in 2021, then decreased by 27.36% to $66.6 million in 2022, then soared by 100.77% to $133.7 million in 2023, then rose by 26.14% to $168.7 million in 2024, then fell by 2.39% to $164.6 million in 2025.
  • Its last three reported values are $164.6 million in Q3 2025, $190.1 million for Q2 2025, and $182.5 million during Q1 2025.